Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 + KN046 in HER2-positive solid tumors
CTR20201699Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- Aug 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab, erfonrilimab in HER2-positive cancer (HER2+), gastric cancer (GC), esophagogastric junction cancer, breast cancer, ovarian cancer, sponsored by Alphamab Oncology. Started Aug 2020; status: completed.
02
Drugs
anbenitamaberfonrilimab
03
Conditions
HER2-positive cancer (HER2+)gastric cancer (GC)esophagogastric junction cancerbreast cancerovarian cancer
Beyond the preview
Go deeper on CTR20201699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201699.